Videos

"We ultimately found that trans women from between the ages of 50 and 65 who were on hormone therapy had a 2.5-fold decreased risk of prostate cancer compared with cis men," says Matthew Loria.

“I think in actuality it's going to have to be one of our trained APPs going to these sites on a scheduled day, like the third Wednesday of every month,” says Tracey L. Krupski, MD.

"Like any test, it's really a very powerful tool. It's just how you deploy the tool," says Edward M. Schaeffer, MD, PhD.

“The hope is that we can collaborate with folks who might be interested in trying nadofaragene plus something else, something that compliments the mechanism of action, so that we can build upon what we have now,” says Vikram M. Narayan, MD.

"We hope that this paper encourages urologists to rethink non definitive treatment/active surveillance for prostate cancer and consider definitive treatment options earlier in the treatment pathway based on evidence that has accumulated," says Mital Patel, MD.

Matthew Smith, MD, PhD, and Brian T. Helfand, MD, discuss the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.

“I think 1 size doesn't fit all. We can't make a blanket statement that 1 of those types of therapy is better for all patients than another,” says Suzette E. Sutherland, MD, MS, FPMRS.

"We know that surgical intervention for ureteroscopy for both renal and ureteral stones does result in a relatively rapid and also quite substantial improvement in quality of life that does exceed preoperative baseline," says Justin B. Ziemba, MD, MSEd.

Panelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.

“I would just say that urologists should be focusing much more on the total amount of pattern 4, if they have that information available, than on the ratio of pattern 3 and 4, and therefore the grade group,” says Andrew J. Vickers, PhD.

"Because it takes advantage of a viral vector and is delivered as a gene therapy product, what it can do is it can have sustained release of IFNα2b in the bladder," says Vikram M. Narayan, MD.

"The point is healthy, adaptive changes that are sustainable, that you can keep off, because we don't want that rebound/regain," says Jill M. Hamilton-Reeves, PhD, RD, CSO.

"PSMA PET imaging is used in the initial diagnostic staging and then in subsequent cases where there can be a recurrence after primary treatment.," says Edward M. Schaeffer, MD, PhD.

“The 1 tweak that's different for our model is that the trained urologist is watching the cysto at the same time as the nurse practitioner is doing it,” says Tracey L. Krupski, MD.

"As most of us know, 1 in 8 couples undergo issues pertaining to fertility, and in about half of those cases, there is a male factor involved, resulting in infertility," says Akash Kapadia, MD.

"We must do more to help surgeons prepare for the impact of adverse events before they happen," says Kevin Turner MA DM FRCS(Urol).

Comprehensive insights on ARPIs (androgen receptor pathway inhibitors) for the treatment of prostate cancer, highlighting what influences treatment decisions and safety profiles of the available APRIs.

Two prostate cancer experts discuss treatment decision-making practices for patients with newly diagnosed metastatic disease.

"One notable finding was that veterans may not have access to the same quality of prostate cancer care as the US general population," says Olubiyi Aworunse, MD, MPH, PhD.

“I think the long and short of it is we know tibial nerve stimulation works, we're just trying to identify what's the best way by which we can deliver it conveniently and cost effectively to the patient,” says Suzette E. Sutherland, MD, MS, FPMRS.

"I continue to be regularly surprised at just how much surgeons are affected when things go wrong, and how little surgeons engage with existing support mechanisms," says Kevin Turner MA DM FRCS(Urol).

In this discussion, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber share their approaches to post-procedure care and follow-up for overactive bladder (OAB) treatments. They detail the patient experience immediately after the procedure, the role of nursing and support staff, and methods for guiding patients through the recovery process, including managing potential complications and effective communication strategies. Additionally, they address challenges in patient adherence to follow-up visits, share insights on assessing treatment effectiveness during these visits, and discuss their strategies for enhancing patient engagement and satisfaction in their practices.

In this episode, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss their strategies for ensuring patient comfort during overactive bladder (OAB) treatment procedures. They delve into the roles of clinical staff, the setup of the procedure room, and how they address patient needs and concerns to create a reassuring environment. The experts also share their experiences in handling challenges during procedures, illustrating how they've adapted their practices based on patient feedback to maintain a patient-centric focus throughout the treatment process.

"What we did find was that a preoperative ureteral stent, and when we did semi rigid ureteroscopy initially, seemed to be protective against worse symptoms," says Justin B. Ziemba, MD, MSEd.

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

In this video, Jaideep S. Sohi, MD, explains how the expanded information provided by PSMA-PET imaging allows physicians to more accurately tailor treatment plans for patients.

“We're always so focused on the prostate. That's the million-dollar question: are we getting to bladders too late?” says Kevin C. Zorn, MD, FRCSC, FACS.

In this video, Jaideep S. Sohi, MD, explains factors to consider regarding the timing of re-imaging with PSMA-PET in patients with prostate cancer.

"PSMA-PET is a radio nucleotide-based imaging modality that really has changed the landscape of how we initially stage and subsequently follow individuals who have a diagnosis of prostate cancer," says Edward M. Schaeffer, MD, PhD.